Compare Albertsons Companies Inc (ACI) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albertsons Companies Inc vs Amphastar Pharmaceuticals Inc — how do they compare? Albertsons Companies Inc trades at $12.25 (market cap $5.89B), while Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M). The key difference: Albertsons Companies Inc is far larger — about 6.8× Amphastar Pharmaceuticals Inc's market cap, and Albertsons Companies Inc pays a 5.61% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ACI | AMPH | |
|---|---|---|
Market Cap | $5.89B | $863.95M |
Sector | Consumer Staples | Health |
52-Week High | $19.74 | $30.81 |
52-Week Low | $11.03 | $16.87 |
Enterprise Value | $21.29B | $1.26B |
Dividend Yield | 5.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albertsons (ACI) trades at $12.01, down 0.58% with bearish technical signals despite recent insider buying by the CEO and CFO. The company reported mixed Q2 2026 earnings with a miss on EPS expectations but maintains strong revenue growth trends. Valuation metrics show a high P/E ratio of 75.06 but attractive P/S of 0.08, while profitability remains challenged with net margins at just 0.08%.
The outlook remains cautious with analyst consensus at Buy (35%) but significant legal investigations and margin pressure creating headwinds. The $13.20 price target offers 10% upside potential, though execution risks and competitive grocery market dynamics require careful monitoring for sustained recovery.
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
